ELAHERE® receives a positive recommendation by Canada’s Drug Agency (CDAAMC) ELAHERE® was submitted for reimbursement review 180 days prior to Health Canada’s approval in line with CDA-AMC’s new Target Zero… Read More
The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG… Read More
EDMONTON, AB – Strengthening international partnerships, GlycoNet and Spain-based CIC bioGUNE have signed a Memorandum of Understanding (MOU) to deepen collaboration in glycomics—the study of complex sugars that coat our… Read More
In two replicate Phase 3 studies, upadacitinib (RINVOQ®) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial… Read More
Based on the DESTINY-Breast06 phase III trial results demonstrating statistically significant and clinically meaningful progression-free survival benefit in patients treated with Enhertu vs. conventional chemotherapy Mississauga, ON – Health Canada… Read More
